The pharmaceutical industry has spent billions developing a monoclonal antibody injection for newborns called nirsevimab, yet a sweeping international study reveals that mothers across eight countries are overwhelmingly rejecting the idea of injecting their infants and instead demanding the vaccine be given to themselves during pregnancy. This is not a story about vaccine hesitancy. This is a story about maternal intuition, about women who understand on a primal level that their bodies are the safest vessels for delivering protection to their unborn children.
The study, published in Vaccine and led by researchers at the University of Applied Sciences and Arts Western Switzerland, surveyed 887 pregnant women across Brazil, Canada, Colombia, Spain, France, Italy, Luxembourg, and Switzerland. The results are unmistakable: 76.1% accepted maternal RSV vaccination, while a staggering 69.8% preferred this method over giving their babies the monoclonal antibody shot at birth. Only 14.5% chose the infant injection, and 9.7% had no preference. The remaining 6% rejected both strategies entirely. The data exposes a fundamental disconnect between what pharmaceutical companies are pushing and what mothers actually want.
Key points:
- 76.1% of pregnant women accepted RSV vaccination during pregnancy.
- 69.8% preferred maternal vaccination over infant monoclonal antibody injection.
- Only 14.5% preferred the infant shot.
- Top reason for maternal preference was avoiding an extra injection for the newborn.
- Women with history of preeclampsia or perceived fetal risk favored the infant antibody.
- 12 infant deaths recorded in clinical trials, mostly attributed to underlying diseases.
- FDA expected to make final decision on nirsevimab in third quarter of this year.
The numbers that tell the real story
The study, conducted between March 2024 and March 2025, cuts through the corporate spin to reveal what women actually want. Of the 887 participants, 96 were already vaccinated during pregnancy, and another 579 preferred to receive the vaccines, instead of their newborn baby getting inoculated. Maternal instinct is universal and spans continents.
The preference for maternal vaccination over infant inoculation ranged from 62.5% in Italy to an eye-opening 81.3% in Brazil. In Brazil, zero percent of women refused both strategies, meaning every single participant wanted to take the shot, but overwhelmingly through their own bodies rather than a needle stuck into their newborn.
The open-ended responses from 442 women who provided additional comments tell the deeper story. The single most cited reason for preferring maternal vaccination was straightforward: avoiding an injection for their future child, cited by 39.2% of respondents. Another 23.3% believed maternal vaccination offered superior efficacy, and 17% preferred the idea of endogenous antibody transfer, the natural process where a mother's immune protection passes to her baby through the placenta. If women were given full informed consent about endogenous antiody transfer, then they'd forgo the interventions altogether and trust their own bodies to convey the immunoglobulins for the infant's defense.
Even though pregnant women are coerced into RSV vaccines now, their instincts and maternal biology are working as nature intended. Women understand that their immune systems, when properly fueled with the right nutrients, can manufacture customized protection that perfectly matches their baby's needs. They instinctively trust their own biology over a laboratory-engineered monoclonal antibody or an experimental vaccines that puts their child at risk to vaccine injury (due to lower blood volume and body weight).
The safety concerns that cannot be ignored
The women who preferred the infant monoclonal antibody had their own reasons, and they are equally revealing. Among those who chose nirsevimab for their babies, 33.8% wanted to avoid potential harmful effects of vaccination during pregnancy. Another 16.2% believed the monoclonal antibody was more effective, and 13.2% cited the lack of long-term pharmacovigilance data on vaccine administration during pregnancy. This is telling. Both the women who took the RSV vaccines and those who deferred their baby to monoclonal antibodies were both trying to protect their child from the vaccine industry lies.
These concerns are not irrational fears. They are informed hesitations grounded in the reality that pregnant women and newborns have been systematically excluded from clinical trials for decades, leaving massive gaps in safety data. The study itself acknowledges this, noting that many women expressed concern about the limited long-term safety research on RSV vaccination during pregnancy.
Meanwhile, the infant monoclonal antibody nirsevimab is not without its own dark cloud. During clinical trials, 12 infant deaths were recorded. Pharmaceutical representatives claim most were due to underlying diseases, not the drug itself. But questions remain about its effectiveness and safety, especially for infants whose mothers have been vaccinated against RSV during pregnancy. The FDA is expected to make a final decision in the third quarter of this year, but Europe, the UK, and Canada have already approved the drug, though it has not yet launched in those markets.
The study authors wrote that their findings highlight the importance of tailored communication addressing pregnant individuals' concerns about safety and efficacy, alongside policies that align with parental vaccination preferences to facilitate effective implementation. This is diplomatic language for a simple truth: pharmaceutical companies and health authorities need to listen to what mothers are telling them.
Sources include:
Please contact us for more information.